The financing will be used to hire additional team members and conduct additional studies in fertility science. The firm also launched its $199 fertility test.
DNA Diagnostics is acquiring all the assets of ContraVac, which markets at-home immunoassays for measuring sperm count.
The firm recently won $4.5 million as well as approval for its Fertilome test from New York state, though some have questioned the test's clinical utility.
The award is one of 121 for projects in New York City this year, totaling $64.8 million.
The company has contracted with a urologist, who will review customers' requests for tests, and prescribe the firm's epigenetics-based male fertility analysis.
A microfluidic phone attachment developed at Brigham and Women's and Mass General may be the precursor of a fertility assay that men can use in the home.